Therapy-Specific Disposable Injection Devices Changing the Drug Delivery Landscape

New Survey by Greystone Associates Examines Device Advances and Market Potential

[ClickPress, Wed Feb 07 2007] While alternative methods for delivering therapeutics to patients have had some notable successes, most drugs continue to be delivered either orally or by injection. Because they cannot tolerate the first-pass metabolism of the digestive tract, the recent escalation in new biological drugs, including antibodies and recombinant proteins, is placing renewed emphasis on drug injection. Now a number of factors are converging to create both risk and opportunity for parenteral drug makers and their device partners. These include new classes of drugs for previously refractory conditions, the growing trend toward self-administration for chronic diseases, shifting patient demographics in industrial countries, caregiver safety legislation, and continued pressure to control healthcare costs.

These factors are giving rise to a new generation of sophisticated, application-specific disposable injection devices designed to satisfy caregiver and patient preferences while addressing managed care initiatives and the limitations of new classes of therapeutic drugs. To achieve commercial success for this new generation of devices, higher levels of cooperation among designers, manufacturers, and developers are needed, and first-line development concepts such as concurrent engineering and design for manufacturing are becoming the rule rather than the exception. Because of their ability to safety and reliably satisfy treatment protocols and compliance goals, these new devices will have a significant impact on the future of patient care.

These findings are contained in a new and comprehensive report: Disposable
Injection Devices: The Next Generation. The report examines the key parameters, players and partnerships that are shaping this segment of the injectable delivery sector.

More information is available at www.greystoneassociates.org .


About Greystone

Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.

Contact:

Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org

Source: Greystone Associates